Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: a longitudinal T2 relaxometry pilot study.
We used magnetic resonance imaging to examine the effect of ethyl-eicosapentaenoic acid (E-EPA) on hippocampal T(2) relaxation time in first episode psychosis patients at baseline and after 12 weeks of follow-up. There was an increase in T(2) in the placebo group but not in the E-EPA group, suggesting a neuroprotective effect of E-EPA treatment. In addition, the smaller the increase in T(2), the greater the improvement in negative symptoms.
Wood
Stephen J
SJ
Melbourne Neuropsychiatry Centre, University of Melbourne, Australia. sjwood@unimelb.edu.au
Cocchi
Luca
L
Proffitt
Tina-Marie
TM
McConchie
Mirabel
M
Jackson
Graeme D
GD
Takahashi
Tsutomu
T
Pantelis
Christos
C
McGorry
Patrick D
PD
Berger
Gregor E
GE
D000293:Adolescent; D000704:Analysis of Variance; D004311:Double-Blind Method; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006624:Hippocampus / Q000187:drug effects; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010865:Pilot Projects; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000473:pathology; D013223:Statistics as Topic; D055815:Young Adult
D018696:Neuroprotective Agents; C035276:eicosapentaenoic acid ethyl ester; D015118:Eicosapentaenoic Acid